智通财经APP讯,百利天恒(688506.SH)发布公告,近日,公司收到国家药品监督管理局的《药品注册证书》,批准公司自主研发的全球首创(First-in-class)、新概念(New concept)且唯一进入III期临床阶段的EGFR×HER3双抗ADC伦康依隆妥单抗(BL-B01D1/iza-bren)上市。
该药品适用于治疗既往经至少二线系统化疗和PD-1/PD-L1抑制剂治疗失败的复发/转移性鼻咽癌患者。
智通财经APP讯,百利天恒(688506.SH)发布公告,近日,公司收到国家药品监督管理局的《药品注册证书》,批准公司自主研发的全球首创(First-in-class)、新概念(New concept)且唯一进入III期临床阶段的EGFR×HER3双抗ADC伦康依隆妥单抗(BL-B01D1/iza-bren)上市。
该药品适用于治疗既往经至少二线系统化疗和PD-1/PD-L1抑制剂治疗失败的复发/转移性鼻咽癌患者。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.